The advantage of PharmaLegacySyngeneic mouse modelis that it can provide more professional and thoughtful solutions timely and accurately according to the actual needs of customers.At the same time, Our company follow the latest developments on Business services,Medical service,Medical insurance, and establish long and steady partnership relation with many well-known enterprises in the same industry , to provide customers with the most professional, advanced DMPK.Details:Immunotherapeutics fight cancer by taking advantage of a patient's own immune system, therefore, preclinical research into new therapies requires appropriate models with fully functional immunity. Syngeneic mouse model (allografts derived from immortalized mouse cancer cell lines which originated from the same inbred strain of mice) provide a valuable system for assessing new single agent, combination immunotherapies, or combination radiotherapy within mice with fully competent immunity. Pharmalegacy provides a panel of well validated syngeneic mouse models for preclinical immunotherapy research, used to interrogating novel immune-oncology treatments via activating the mouse immune system. We have model types include subcutaneous, orthotopic and metastatic. Our suite of syngeneic mouse model includes 22 models covering 14 cancer types and more on going, which validated with anti-PD-1, PD-L1 and anti-CTLA-4 antibodies